NR3C2 and chronic kidney disease: This demonstrates that treatment with finerenone, a MR blockade, as compared with placebo reduces CKD progression by (hazard ratio, 0.82; 95% confidence interval [CI], 0.73 to 0.93; p = 0.001) and cardiovascular events by (hazard ratio, 0.86; 95% CI, 0.75 to 0.99; p = 0.03) [34].